ALXN - Alexion Pharmaceuticals, Inc.
| Previous Close | 123.49 |
| Open | 123.12 |
| Bid | 115.50 x 900 |
| Ask | 118.50 x 800 |
| Day's Range | 114.93 - 124.02 |
| 52 Week Range | 92.56 - 141.86 |
| Volume | 5,246,754 |
| Avg. Volume | 1,976,190 |
| Market Cap | 25.86B |
| Beta (3Y Monthly) | 1.70 |
| PE Ratio (TTM) | 19.54 |
| EPS (TTM) | 5.90 |
| Earnings Date | Oct 22, 2019 - Oct 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 158.94 |
- Motley Fool
Should Amgen Finally Buy Alexion Pharmaceuticals?
One of biotech's longest-running buyout rumors is picking up steam again.
- Motley Fool
3 Reasons Why Amgen Could Actually Acquire Alexion
Rumors that Amgen plans to buy Alexion might not become reality. But a deal would make a lot of sense.
- Investor's Business Daily
Why Alexion Makes Sense As A Target, But Amgen Doesn't As A Buyer
Alexion Pharmaceuticals is likely "on the radar" as a takeover candidate, but biotech company Amgen doesn't fit logically as an acquirer, an analyst said. Alexion stock toppled Friday.
- Market Realist
Amgen’s Alexion Acquisition: Does It Make Sense?
On August 21, Spanish website Intereconomia reported that Amgen would be announcing its acquisition of Alexion Pharmaceuticals in the next few days.
- Zacks
Why Is Alexion (ALXN) Up 4.6% Since Last Earnings Report?
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Investor's Business Daily
Biotech Giant Amgen Could Be Nearing A Massive Takeover: Report
Biotech giant Amgen could be nearing a deal to buy Alexion Pharmaceuticals at a 74% premium, according to a Spanish news outlet. The deal values Alexion stock at $200 a share.
- Zacks
Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 7.5%
Alexion Pharmaceuticals (ALXN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- TheStreet.com
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
- TheStreet.com
Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid
Mizuho's Salim Syed says talk of possible tieup isn't far-fetched. Alexion and Amgen decline comment.
- Zacks
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
- Zacks
NuCana Stops Patient Enrollment in Pancreatic Cancer Study
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.
- Zacks
Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why
Alexion (ALXN) possesses solid growth attributes, which could help it handily outperform the market.
- Zacks
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
- Zacks
Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
- Zacks
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?
Is (ALXN) Outperforming Other Medical Stocks This Year?
- Zacks
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
- Reuters
Canadian drug price regulator may be flexible on rare diseases
Canada's patented drug price regulator, set to gain new powers next year, may be "more forgiving" in setting price caps for drugs that treat rare diseases, the agency's executive director told Reuters, as some advocates warned the country's pricing reforms would hurt patients. The Canadian government announced final regulations meant to cut drug spending on Friday. The reforms expand the Patented Medicine Prices Review Board's (PMPRB) powers, and among other things give it the ability to consider the cost-effectiveness of medications.
- Zacks
Mergers & Acquisitions Take Center Stage in Biotech Industry
Mergers & Acquisitions Take Center Stage in Biotech Industry
- Zacks
Can Value Investors Consider Alexion (ALXN) a Worthy Pick?
Alexion (ALXN) stock may be a good choice for value-oriented investors right now from multiple angles.
- Motley Fool
Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals
Two great biotechs focused on rare diseases. But one of them gets the nod as the better pick.
- Zacks
ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
ALXN vs. CBM: Which Stock Is the Better Value Option?
- Zacks
Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
- Zacks
Biotech ETFs in Focus on Impressive Q2 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
- Zacks
Looking for a Growth Stock? 3 Reasons Why Alexion (ALXN) is a Solid Choice
Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
